3 ms·
This is getting depressingly common. I don't know the answer to this problem. There is a super expensive treatment for cystic fibrosis that only helps about 5%
by Mz 12y ago
This is getting depressingly common. I don't know the answer to this problem. There is a super expensive treatment for cystic fibrosis that only helps about 5% of the population and is something like a quarter million dollars a year and is not a cure. People with CF almost never have that kind of money. Unless they were born into a very wealthy family, having one family member with CF is such a huge financial and practical burden on the family that most folks with this in the family are not financially comfortable. Some of them are incredibly destitute.
I get that these very expensive pills are sort of "miracle cures" and the price is intended to reflect that fact and cover the high costs of development and all that, but this is a fundamentally broken system. I don't know what the world needs to do here, but this is just crazy.
- maxerickson 12y agoSome of that cost got funneled back into CF research: http://www.cff.org/aboutCFFoundation/NewsEvents/11-19-Expansion-of-Research-and-Programs.cfm http://www.cff.org/aboutCFFoundation/NewsEvents/11-19-Expans... (I guess you mean Ivacaftor, the Cystic Fibrosis Foundation sold their royalty rights for $3.3 billion.) To a large extent, the insurance companies are setting the prices on these drugs (getting charged whatever the max they will pay). I think part of the solution might be somewhat counter intuitive, to throw even more resources at the early stage research, with the hope that there is more competition by the time things make it to patients.
- Mz 12y agoAccording to other people more in-the-know than I am, the CF Foundation is basically in bed with big pharma. They are not really looking for better care for people with CF. They are looking specifically for better drugs. So, most likely, that money is being funneled back into more drug research -- more of this type thing. I am not so sure that's really some kind of silver lining.
- maxerickson 12y agoI posted the cost part of the comment because I was pondering structural incentives and in that context, found out that particular drug had a foundation partner. I wasn't necessarily trying to weigh in on the good or the bad of it. Short of gene therapy, addressing the defective protein is pretty much going to be done with drugs, so I don't find it particularly telling that they are putting resources there. CFF does seem to be involved in clinical care (but I'm not informed enough to figure out how much of that is self promotion and how much is substantive). Anyway, the main point I had intended was that the price isn't just a function of what the company wants it to be, the buyers have to be willing to pay it (which sounds gross when talking about health care, but national health systems and insurance companies do worry some about whether treatments are worth what they cost).
- deleted 12y ago[deleted]
- Mz 12y agoHey, I am sending you an email.
- refurb 12y agoThey are not really looking for better care for people with CF. They are looking specifically for better drugs. This is an odd comment. The drug in question, Kalydeco, is the first drug that actually reserves some of the defect that causes CF. How is coming up with such a drug not improving CF care?
- Mz 12y agoThere is more to taking care of people than just prescribing drugs. Those other avenues are largely ignored for people with CF. And, again, the drug in question only helps something like 5% of the population. It is mutation specific. If you do not have the mutation it helps, you are completely out in the cold. Plus, CF is genetic. It is not like treating an infection where if you give enough of X drug, it goes away. So my understanding is that Kalydeco is around $250k per year for life. I don't know about you, but that looks like a really steep price tag to me. Most folks do not make that kind of money. They just don't. Edit: And that is before we even get into the controversies I have seen on CF lists about them possibly spin-doctoring their data in order to get the stock price up or some such (I honestly didn't pay too much attention).